State Prescription Drug Purchase Standards | ||||||||||||||||||||||
| Results | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||
 Results by county
| ||||||||||||||||||||||
| Source: California Secretary of State[1] | ||||||||||||||||||||||
| Elections in California |
|---|
 |
Proposition 61 was a California ballot proposition that appeared on the November 8, 2016 ballot. It would have prohibited the state of California from buying any prescription drug from a drug manufacturer at price over the lowest price paid for the drug by the United States Department of Veterans Affairs. It would have exempted managed care programs funded through Medi-Cal.[2] According to the fiscal impact statement issued by California Legislative Analyst's Office, "potential for state savings of an unknown amount depending on (1) how the measure’s implementation challenges are addressed and (2) the responses of drug manufacturers regarding the provision and pricing of their drugs."[3]
Proposition 61 was rejected by a vote of 47 to 53 percent.[4]
- ^ "Statement of Vote - November 8, 2016, General Election". December 16, 2016. Retrieved January 7, 2017.
- ^ "Proposition 61. California General Election November 8, 2016. Official Voter Information Guide". California Secretary of State. Archived from the original on 15 September 2016. Retrieved 10 October 2016.
- ^ Taylor, Mac; Cohen, Michael. "Fiscal Impact Statement" (PDF). State of California Department of Justice Office of the Attorney General. Retrieved 11 October 2016.
- ^ Sernoffsky, Evan (November 9, 2016). "California voters reject drug-price measure Prop 61". SFGate. Retrieved December 7, 2016.